Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation

NCT06990529 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

PIDs Linked to PI3K

Interventions

DRUG: Leniolisib

Sponsor

Pharming Technologies B.V.

Collaborators

[object Object]